Sex: F
Vaccine: RAB
Symptoms: Antibody test abnormal, No adverse event, Therapy non-responder
Clinical narrative: The patient's titer responded that was not resistant; Case reference number US-BN-2022-002591 is a spontaneous case report initially received on 16-Sep-2022 from other health care professional via Communication (reference number: USBAV22-1439) and concerns a *42-year-old female patient*.   The patient's medical history and concomitant medication details were not provided.   On 06-Aug-2021, the patient was vaccinated with the first dose of RabAvert (Rabies Virus (Inactivated, Strain Flury LEP) (PCEC); batch number: ARBA171, expiration date 31-Jul-2022) at an unknown dose, via unknown route of administration *in the upper arm*, for *prophylaxis due to working in a laboratory*.  On an unspecified date, an unknown amount of time after the first RabAvert dose and reported as within four months, the patient's titer responded that she was not resistant. The patient stated that she checked with her doctor for further actions and the patient's doctor asked for an expiration date of the vaccine. However, the expiration date was not recorded at the time of vaccination and the patient only had a batch number.   *As reported, the patient did not experience any adverse event due to RabAvert vaccination.*  *At the time of this follow up report, the outcome of the event 'antibody result abnormal' remained unknown.  The reporter assessed the event of 'antibody result abnormal' as non-serious. The reporter did not provide a causality assessment.  Additional information received on 20-Sep-2022 included local case ID.  Additional information received on 21-Sep-2022 included expiration date for the RabAvert vaccine and product complaint form confirming no product quality complaint was associated with the case.  All follow-up information is blended into the case narrative above, with the latest information presented between asterisks (*).  Follow-up information received from other healthcare professional on 02-Nov-2022: New information included patients' details, indication and anatomical site of administration, and confirmation that the patient did not experience any adverse event.; Reporter's Comments: A 42-year-old female patient received the first dose of RabAvert on 06-Aug-2021 (batch number: ARBA171 with expiration date 31-Jul-2022), applied at an unknown dose, in the upper arm of administration, for prophylaxis due to occupational exposure. An unspecified amount of time after the first dose, reported as approximately four months later, the patient got tested for antibody titer. The numerical result was not reported, however, patient reported being told they were 'not resistant'. According to the Manufacturer's data, the vaccine had not expired at the time of administration. The patient did not experience adverse events following vaccination with RabAvert. Antibody result abnormal is unlisted per the guidelines. The patient's medical history and concomitant medications were unknown. It was unknown if the patient received more than one dose of RabAvert as part of their vaccination course. Considering the limited information available, and that no exact antibody result was reported, the event is assessed as related to RabAvert. The case is non-serious.; Sender's Comments: A 42-year-old female patient received the first dose of RabAvert on 06-Aug-2021 (batch number: ARBA171 with expiration date 31-Jul-2022), applied at an unknown dose, in the upper arm of administration, for prophylaxis due to occupational exposure. An unspecified amount of time after the first dose, reported as approximately four months later, the patient got tested for antibody titer. The numerical result was not reported, however, patient reported being told they were 'not resistant'. According to the Manufacturer's data, the vaccine had not expired at the time of administration. The patient did not experience adverse events following vaccination with RabAvert. Antibody result abnormal is unlisted per the guidelines. The patient's medical history and concomitant medications were unknown. It was unknown if the patient received more than one dose of RabAvert as part of their vaccination course. Considering the limited information available, and that no exact antibody result was reported, the event is assessed as related to RabAvert. The case is non-serious.